Yesterday, July 13, 2016, 34 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $12.18 to $16,703,820.00.

Highlighted Stocks Traded by Insiders:

Medidata Solutions (MDSO) - FREE Research Report

De Vries Glen Michael, who is President at Medidata Solutions, sold 32,500 shares at $49.25 on July 13, 2016. Following this transaction, the President owned 990,153 shares meaning that the stake was reduced by 3.18% with the 32,500-share transaction.

Sherif Tarek, who is Chairman & CEO at Medidata Solutions, sold 22,036 shares at $49.24 on July 13, 2016. Following this transaction, the Chairman & CEO owned 877,580 shares meaning that the stake was reduced by 2.45% with the 22,036-share transaction.

The shares most recently traded at $48.49, down $0.75, or 1.55% since the insider transaction. Historical insider transactions for Medidata Solutions go as follows:

  • 4-Week # shares bought: 1,500
  • 4-Week # shares sold: 17,500
  • 12-Week # shares bought: 1,500
  • 12-Week # shares sold: 169,386
  • 24-Week # shares bought: 1,500
  • 24-Week # shares sold: 169,386

The average volume for Medidata Solutions has been 362,500 shares per day over the past 30 days. Medidata Solutions has a market cap of $2.8 billion and is part of the technology sector and computer software & services industry. Shares are down 1.74% year-to-date as of the close of trading on Wednesday.

Medidata Solutions, Inc. provides cloud-based solutions for life sciences worldwide. The company offers applications and data analytics for clinical development. The company has a P/E ratio of 147.9. Currently, there are 8 analysts who rate Medidata Solutions a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on MDSO - FREE

TheStreet Quant Ratings

rates Medidata Solutions as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including premium valuation, weak operating cash flow and a generally disappointing performance in the stock itself. Get the full

Medidata Solutions Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

A10 Networks (ATEN) - FREE Research Report

Cochran Robert D, who is VP, Legal & Corp Collaboration at A10 Networks, sold 5,000 shares at $7.00 on July 13, 2016. Following this transaction, the VP, Legal & Corp Collaboration owned 178,728 shares meaning that the stake was reduced by 2.72% with the 5,000-share transaction.

The shares most recently traded at $7.00, down $0.00, or 0.03% since the insider transaction. Historical insider transactions for A10 Networks go as follows:

  • 4-Week # shares bought: 20,000
  • 4-Week # shares sold: 5,000
  • 12-Week # shares bought: 20,000
  • 12-Week # shares sold: 5,000
  • 24-Week # shares bought: 38,342
  • 24-Week # shares sold: 5,000

The average volume for A10 Networks has been 359,000 shares per day over the past 30 days. A10 Networks has a market cap of $457.1 million and is part of the technology sector and telecommunications industry. Shares are up 7.01% year-to-date as of the close of trading on Wednesday.

A10 Networks, Inc. provides software based application networking and network security solutions in the United States, Japan, and internationally. Its solutions are built on advanced core operating system platform. Currently, there are 5 analysts who rate A10 Networks a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ATEN - FREE

TheStreet Quant Ratings

rates A10 Networks as a

sell

. The area that we feel has been the company's primary weakness has been its disappointing return on equity. Get the full

A10 Networks Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Allscripts Healthcare Solutions (MDRX) - FREE Research Report

Olis Dennis, who is SVP of Operations at Allscripts Healthcare Solutions, sold 7,000 shares at $14.00 on July 13, 2016. Following this transaction, the SVP of Operations owned 210,887 shares meaning that the stake was reduced by 3.21% with the 7,000-share transaction.

The shares most recently traded at $14.16, up $0.16, or 1.13% since the insider transaction. Historical insider transactions for Allscripts Healthcare Solutions go as follows:

  • 4-Week # shares bought: 6,500
  • 4-Week # shares sold: 25,000
  • 12-Week # shares bought: 6,500
  • 12-Week # shares sold: 25,000
  • 24-Week # shares bought: 6,500
  • 24-Week # shares sold: 87,500

The average volume for Allscripts Healthcare Solutions has been 2.2 million shares per day over the past 30 days. Allscripts Healthcare Solutions has a market cap of $2.6 billion and is part of the technology sector and computer software & services industry. Shares are down 8.78% year-to-date as of the close of trading on Wednesday.

Allscripts Healthcare Solutions, Inc. provides information technology and services to healthcare organizations in the United States, Canada, and internationally. The company has a P/E ratio of 235.3. Currently, there are 11 analysts who rate Allscripts Healthcare Solutions a buy, no analysts rate it a sell, and 11 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MDRX - FREE

TheStreet Quant Ratings

rates Allscripts Healthcare Solutions as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full

Allscripts Healthcare Solutions Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.